BioMarin's 20% Yuviwel Royalty Is a Bridge, Not a Win

BioMarin (BMRN) just got paid by the drug that is taking its market. On August 31, Ascendis Pharma (ASND) agreed to pay BioMarin a 20% royalty on U.S. net sales of Yuviwel, its once-weekly achondroplasia treatment, plus 18% on sales in the EU, Brazil, and South Korea, running through May 2030. In exchange, BioMarin drops every lawsuit, including the International Trade Commission Section 337 case that could have produced an import ban on Yuviwel, and grants Ascendis a broad license covering current and future indications, hypochondroplasia included.

The analyst chorus called it a “win-win.” BMO flagged the rate as “high-end,” and Stifel said 18% to 20% sits “at the high end” of recent biotech patent settlements. That framing names the winner backwards. BioMarin just monetized the loss of its flagship franchise, and it did so at a rate that recovers 20 cents for every dollar of Voxzogo revenue Yuviwel takes away.

The two drugs compete directly. Both are C-type natriuretic peptide (CNP) therapies for achondroplasia, the most common form of dwarfism, caused by an overactive FGFR3 signal that suppresses bone growth. Voxzogo is BioMarin’s daily subcutaneous injection, approved in November 2021 on a statistically significant improvement in annualized growth velocity versus placebo. Yuviwel is Ascendis’ once-weekly injection, cleared in February 2026 after its ApproaCH registrational trial, which was published in JAMA Pediatrics. Weekly dosing is the entire pitch: the same mechanism, one shot a week instead of seven.

BioMarin’s own numbers show how fast the switch is coming. In July, the company said 90% of its U.S. patient base was still on Voxzogo, but that share is expected to shift toward the weekly option over time. The hypochondroplasia data is where the royalty’s upside lives. BioMarin’s Phase 3 readout in May showed efficacy “solidly above” what Voxzogo delivers in achondroplasia, and Ascendis’ COACH combination posted Week 78 mean annualized growth velocity of 7.7 cm/year, at or above the 97th percentile for children of average stature. A second indication with a larger effect size is exactly the scenario that turns a 20% royalty from a consolation prize into a meaningful annuity.

Put a number on the trade. Voxzogo generated $253 million in Q2 2026, up 14% year over year, and BioMarin just raised full-year guidance to the low end of $1 billion. It is the largest product in a company that did $990 million in total Q2 revenue. Yuviwel is approved but early, at €7.6 million (about $8.5 million) in Q2 revenue after an April launch. If Yuviwel follows the weekly-convenience playbook and captures 40% of a $1 billion-plus U.S. market by 2028, that is roughly $400 million in Yuviwel sales and $80 million a year in BioMarin royalties. Meanwhile BioMarin surrenders a similar amount of Voxzogo revenue, because most Yuviwel patients switch from Voxzogo. Net the two and BioMarin trades a dollar of its own product revenue for 20 cents of someone else’s. That is a hedge, not a victory.

The royalty is still real money. Jefferies estimates it is worth $280 million in U.S. royalties and $440 million non-U.S. by 2030, about $720 million in total. Against BioMarin’s $12.55 billion market cap at $64.84 a share, that is roughly 5.7% of market cap spread across four years. It partly offsets Voxzogo erosion, exactly as William Blair described. It does not replace it.

So why did BioMarin settle instead of fighting for the import ban? An ITC exclusion order would have removed Yuviwel from the U.S. entirely and protected Voxzogo outright. The fact that BioMarin took 20% instead tells you its patent position was shakier than the “win-win” headline admits. BioMarin’s patent covers long-acting CNP variants. If the ITC or a court had invalidated that claim, BioMarin would have collected nothing and, worse, weakened the intellectual property protecting BMN 333, its own once-weekly CNP now in Phase 3. Settling preserves the patent and converts it into a guaranteed cash stream. The rate is high precisely because BioMarin needed the deal.

For Ascendis, the settlement is cheaper than it looks. The royalty drags on Yuviwel margins, but this is a premium-priced rare-disease drug; Voxzogo lists at $320,000 a year, and Yuviwel competes at a similar level. A 20% royalty on a high-margin product is absorbable. What Ascendis bought for that 20% is the removal of the one existential threat to its franchise, an import ban that would have made its U.S. launch illegal, plus a license that covers the combination of TransCon CNP with human growth hormone, Ascendis’ COACH program, and its planned Phase 3 in hypochondroplasia.

That last part is what the market is under-pricing. Ascendis’ Q2 was carried by YORVIPATH, its hypoparathyroidism drug, at €252 million, more than double the prior year, while Yuviwel is still a rounding error at €7.6 million. Total Q2 revenue hit €339 million, up 115% year over year. On an annualized basis Ascendis trades near 11x revenue, more than three times BioMarin’s multiple, which is the market saying it already believes the weekly franchise wins. Yet Ascendis’ $17.07 billion market cap, more than $4.5 billion above BioMarin’s, is not being driven by Yuviwel today. It is a bet that the once-weekly CNP franchise, the combo, and hypochondroplasia become the growth engine after YORVIPATH matures. The settlement just removed the biggest legal obstacle to that bet.

There is a third entrant. BridgeBio’s infigratinib, an oral FGFR3 inhibitor, is in Phase 3 for achondroplasia. A pill is a different convenience proposition than even a weekly injection, and it pressures both CNP players on price. BioMarin’s defensive answer is BMN 333, its once-weekly CNP, with Phase 3 data due in 2027. On hypochondroplasia, BioMarin reported positive Phase 3 Voxzogo data in May 2026 that was “solidly above” the drug’s achondroplasia efficacy, and it plans an sNDA filing by year-end; Ascendis is launching its own hypochondroplasia Phase 3. The franchise is about to get crowded, which is another reason the royalty’s value peaks early and then gets squeezed from both sides.

The risks are not symmetric. For BioMarin, the risk is that Voxzogo erodes faster than the royalty offsets it, and that BMN 333 misses or arrives late. The royalty expires in May 2030, right around when BMN 333 would need to carry the franchise; if BMN 333 is late, BioMarin is left with a shrinking Voxzogo and no royalty. For Ascendis, the risk is margin compression from the royalty plus a competitor in the class, but that is ordinary business risk, not the existential kind. The import ban is gone.

There is a repeatable lesson here, and it is the same one that plays out whenever a dosing-interval upgrade hits a rare-disease market. The daily-shot incumbent has two choices: fight the weekly challenger in court, or take a royalty and redirect capital to its own next-generation product. BioMarin chose the second. It is the rational choice for the incumbent, but it is also the choice that confirms the challenger has already won the dosing argument. When a company starts collecting royalties on its own replacement, the growth story has already moved.

The verdict: BioMarin is a hold, not a buy. The royalty is a bridge to BMN 333, but a bridge does not change the fact that the flagship is eroding and the next re-rating catalyst is not near term. At roughly 3x sales for a company whose largest product is losing share, the multiple looks fair, not cheap. For how the Voxzogo franchise stacks up against other rare-disease catalysts, see the rare disease catalyst roundup and the earlier Voxzogo sNDA primer. BioMarin’s diversification beyond the skeleton, like its Alesta acquisition in hypophosphatasia, does not change that arithmetic yet.

Ascendis is the better risk-reward, though not a screaming buy at $260. The settlement removed the tail risk that kept a discount on the stock, and the CNP franchise is real. The setup worth watching is the one the settlement just enabled: if the hypochondroplasia readout and the combo data keep printing best-in-class numbers, the market re-rates the CNP franchise from optionality into a second $1 billion-plus product. That is where the next move comes from, and it favors Ascendis.

Sources: BioMarin’s settlement announcement and Fierce Pharma’s breakdown of the terms.